| CPC A61K 38/48 (2013.01) [C12N 9/52 (2013.01)] | 10 Claims |
|
1. A method of treating an immune dysregulation disorder, said method comprising administering a therapeutically effective amount of an isolated protease comprising a polypeptide having the structure:
P-A-B
wherein P is a protease domain, A is an A-domain, and B is a B-domain, of a Group VII to XIII cell envelope protease (CEP), wherein the protease does not have a PA domain, and wherein the immune dysregulation disorder is selected from the group consisting of;
(i) a disorder associated with dysregulation of C5a, selected from the group consisting of sepsis, skin disease, transplant rejection, lyme disease, arthritis, cancer, cystic fibrosis, allergic asthma and age-related macular degeneration (AMD);
(ii) a disorder associated with dysregulation of C3a selected from the group consisting of kidney disease, and age-related macular degeneration (AMD);
(iii) a disorder associated with dysregulation of IL-8 and selected from the group consisting of ulcerative colitis, cancer, gingivitis, psoriasis, inflammatory lung disease and glomerulonephritis;
(iv) a disorder associated with dysregulation of IL-17 selected from the group consisting of psoriasis, allergy response, autoimmune disorder, asthma, eczema, multiple sclerosis, arthritis, and inflammatory bowel disease;
(v) a disorder associated with dysregulation of IL-1β selected from the group consisting of rheumatoid arthritis, and diabetes;
(vi) a disorder associated with dysregulation of TNF-α selected from the group consisting of rheumatoid arthritis, ankylosing spondylitis, Alzheimer's disease, cancer, psoriasis, and inflammatory bowel disease;
(vii) a disorder associated with dysregulation of IL-6 selected from the group consisting of rheumatoid arthritis, transplant rejection and cancer; and
(viii) a disorder associated with dysregulation of IL-3 selected from the group consisting of allergic inflammation, leukemia, and rheumatoid arthritis.
|